Immunic (IMUX) Net Cash Flow (2013 - 2026)

Immunic has reported Net Cash Flow for 14 years, with the latest figure at $171.3 million in Q1 2026.

• Quarterly Net Cash Flow rose 885.13% year-over-year to $171.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172.8 million (up 308.72% YoY) and the FY2025 annual result came in at -$20.4 million, down 94.39% from the prior year.
• Net Cash Flow improved to $171.3 million in Q1 2026 per IMUX's latest filing, from -$19.2 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $171.3 million in Q1 2026 and troughed at -$22.9 million in Q4 2024.
• A 5-year average of $5.9 million and a median of -$14.1 million in 2023 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2026: Net Cash Flow slumped 257.84% in 2023, then jumped 885.13% in 2026.
• Over 5 years, Net Cash Flow stood at $31.3 million in 2022, then plunged by 143.4% to -$13.6 million in 2023, then plunged by 68.45% to -$22.9 million in 2024, then advanced by 15.97% to -$19.2 million in 2025, then soared by 990.86% to $171.3 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $171.3 million, -$19.2 million, and -$20.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.